NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Congress Co-Moderators

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.  

Anthony J. Olszanski, MD, RPh  
Bristol-Myers Squibb Company: Scientific Advisor 
Eisai Inc.: Scientific Advisor  
InstilBio: Scientific Advisor  
Merck & Co., Inc.: Scientific Advisor  
Nektar Therapeutics: Scientific Advisor  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Oncosec Immunotherapies: Scientific Advisor 
Pfizer Inc.: Honoraria 
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor 

Tuya Pal, MD 
Natera, Inc.: Scientific Advisor 

Presenting Faculty

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Harold J. Burstein, MD, PhD  
Craig M. Horbinski, MD, PhD 
Lawrence J. Jennings, MD, PhD  
Grace Y. Lin, MD, PhD 
Daniel J. McGrail, PhD  
Lisa Schlager 
Randy Vince Jr., MD, MS 

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Devon Adams, RN, MPH  
Amgen Inc.: Grant/Research Support  
Bayer HealthCare: Grant/Research Support 
Blueprint Medicines: Grant/Research Support 
Bristol-Myers Squibb Company: Grant/Research Support 
EMD Serono: Grant/Research Support 
Foundation Medicine, Inc.: Grant/Research Support 
Genentech, Inc.: Grant/Research Support 
Janssen Pharmaceutica Products, LP: Grant/Research Support 
Merck & Co., Inc.: Grant/Research Support 
NeoGenomics Laboratories, Inc.: Grant/Research Support 
Pfizer Inc.: Grant/Research Support 
sanofi-aventis U.S.: Grant/Research Support 

Gabriel A. Bien-Willner, MD, PhD 
Guardant Health: Equity Interest/Stock Options 
Illumina, Inc.: Scientific Advisor 
Merck & Co., Inc.: Scientific Advisor

Aparna Kalyan, MD 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor 
Boston Scientific Corporation: Consulting Fee; Honoraria; Scientific Advisor
Exelixis Inc.: Consulting Fee; Honoraria; Scientific Advisor
Genentech, Inc.: Consulting Fee; Honoraria; Scientific Advisor
QED Therapeutics, Inc.: Consulting Fee; Scientific Advisor

Rimas V. Lukas, MD  
Bristol-Myers Squibb Company: Grant/Research Support 
Merck & Co., Inc.: Product/Speakers Bureau; Scientific Advisor 
Novocure: Product/Speakers Bureau 

Jennifer Morrissette, PhD  
AbbVie, Inc.: Consulting Fee 
Illumina, Inc.: Consulting Fee 
Thermo Fisher Scientific, Inc.: Equity Interest/Stock Options  

Sandip P. Patel, MD 
Amgen Inc.: Grant/Research Support; Scientific Advisor 
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor 
Eli Lilly and Company: Scientific Advisor 
Fate Therapeutics: Grant/Research Support  
Genentech, Inc.: Grant/Research Support; Scientific Advisor 
Iovance pharmaceuticals: Grant/Research Support; Scientific Advisor 
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor 
Novartis Pharmaceuticals Corporation: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor 
SQZ Biotech, Inc.: Grant/Research Support  

Daniel E. Spratt, MD  
Bayer HealthCare: Consulting Fee 
Blue Earth Diagnostics: Honoraria 
Novartis Pharmaceuticals Corporation: Honoraria 
Pfizer Inc.: Honoraria 
Varian Medical Systems, Inc.: Honoraria

Howard (Jack) West, MD  
Amgen Inc.: Consulting Fee 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Boehringer Ingelheim GmbH: Consulting Fee 
Daiichi-Sankyo Co.: Consulting Fee  
Genentech/Roche: Consulting Fee  
Merck & Co., Inc.: Consulting Fee; Product/Speakers Bureau  
Mirati Therapeutics, Inc.: Consulting Fee  
Regeneron Pharmaceuticals, Inc.: Consulting Fee 
Summit Therapeutics Inc.: Consulting Fee 
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Moderator/Planner Disclosures

The moderator/planner listed below has the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated. 

Crystal S. Denlinger, MD 
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support 
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support 
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support 
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor 
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor 
Zymeworks: Scientific Advisor; Grant/Research Support 

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.